Danaher Co. (NYSE:DHR) Shares Sold by SeaCrest Wealth Management LLC

SeaCrest Wealth Management LLC decreased its position in Danaher Co. (NYSE:DHR) by 38.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,184 shares of the conglomerate’s stock after selling 739 shares during the quarter. SeaCrest Wealth Management LLC’s holdings in Danaher were worth $296,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Cary Street Partners Investment Advisory LLC grew its position in Danaher by 20.2% in the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock valued at $2,112,000 after acquiring an additional 1,533 shares in the last quarter. First Citizens Bank & Trust Co. grew its position in shares of Danaher by 0.6% during the fourth quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock worth $6,156,000 after buying an additional 149 shares in the last quarter. Cercano Management LLC grew its position in shares of Danaher by 11.4% during the fourth quarter. Cercano Management LLC now owns 202,569 shares of the conglomerate’s stock worth $46,862,000 after buying an additional 20,715 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of Danaher by 48.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock worth $68,707,000 after buying an additional 96,395 shares in the last quarter. Finally, Caden Capital Partners LP grew its position in shares of Danaher by 12.4% during the fourth quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock worth $32,172,000 after buying an additional 15,313 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Danaher in a research report on Monday, June 3rd. They set a “buy” rating and a $295.00 price target for the company. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Bank of America raised their price target on shares of Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 24th. Robert W. Baird raised their price target on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. Finally, Barclays raised their price objective on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 24th. Six investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $268.67.

Insider Activity at Danaher

In related news, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the sale, the director now directly owns 116,202 shares in the company, valued at $28,304,483.16. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the sale, the chief executive officer now directly owns 115,995 shares in the company, valued at $28,908,273.90. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the sale, the director now owns 116,202 shares in the company, valued at $28,304,483.16. The disclosure for this sale can be found here. Insiders have sold a total of 148,783 shares of company stock worth $37,536,717 over the last ninety days. 10.90% of the stock is currently owned by corporate insiders.

Danaher Stock Performance

DHR stock opened at $240.21 on Thursday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. The stock has a market capitalization of $177.92 billion, a price-to-earnings ratio of 40.68, a PEG ratio of 3.82 and a beta of 0.84. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $269.11. The stock’s fifty day moving average is $255.88 and its two-hundred day moving average is $246.95.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm’s quarterly revenue was down 2.6% compared to the same quarter last year. During the same period last year, the business posted $2.36 earnings per share. On average, research analysts predict that Danaher Co. will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date is Friday, June 28th. Danaher’s payout ratio is 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.